AstraZeneca (AZN.US) subsidiary ADC drug Datroway receives FDA approval for the treatment of EGFR mutant non-small cell lung cancer.

According to the Securities Times APP, the antibody-drug conjugate (ADC) Datroway developed by AstraZeneca (AZN.US) and its partner Daiichi Sankyo has been approved by the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic EGFR mutation non-small cell lung cancer (NSCLC) in adult patients who have previously received EGFR targeted therapy and platinum-based chemotherapy. This approval provides a new treatment option for EGFR mutation NSCLC patients after multiple-line treatment. AstraZeneca also added that this is the first drug approved in the United States for the treatment of this type of lung cancer.